Local
Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug
A Roundtable is a way to meet new people and discuss this article in person at a local coffee shop or other venue.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Investor's Business Daily

Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab.
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Investor's Business Daily



